💊 Novavax exits Gavi deal; Telangana’s Pharma City builds on farmer lands; Have you had your tea yet?
#222 | GSK laying off staff in India
Hello, and welcome back to The Kable. Research says Wednesdays are the best days to work on your CV. Especially if you're working with GSK in India. Even more so if you are among the 150 people being let go.
Yesterday the WHO said it is preparing a list of pathogens that can cause the next pandemic. The US National Institute of Allergy and Infectious Diseases is going one-up by awarding three institutions more than $12 million to develop antiviral therapies to treat diseases caused by pandemicky viruses.
In what has already been a record year for expensive gene therapies, a new haemophilia treatment has gotten the US FDA's nod. And this particular gene therapy is priced at $3.5 million. Money? What is money anymore?
And finally, the WHO has been mulling a name change for monkeypox for a while now to avoid any stigma. The agency is settling on MPOX as the new name.